Novartis Home

The Novartis Compound Library provides automated storage for experiments.

At Novartis, we are reimagining medicine

Novartis Financial Results – Q2 2019

Novartis announced the company’s financial results for the second quarter and first half of 2019.

Video - Novartis Financial Results

Our Executive Team talks about innovation highlights from the second quarter of 2019.

Watch video

Activated T-cells (shown in blue) attack and destroy a cancer cell.

Cell & Gene Therapy at Novartis

Our teams aim to deliver on the promise of cell and gene therapy for patients.

Transparency

Disclosure of transfers of value to healthcare professionals and support to patient groups in accordance with EFPIA Codes and other local laws and regulations.

Payments to Healthcare Professionals
Patient Organization Funding

Novartis Home

At Novartis, we are reimagining medicine

Novartis Financial Results – Q2 2019

Video - Novartis Financial Results

Cell & Gene Therapy at Novartis

Novartis key multiple sclerosis product Gilenya® approved in China

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention